Friday, June 3, 2022

Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported.

from Top Health News -- ScienceDaily https://ift.tt/0LH9PVY
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Stanford scientists discover the human brain may actually be two separate organs

Scientists have found that the human brain develops from two distinct cellular systems, suggesting that evolution fused together two ancient...